Semma is working to bring this new therapeutic option to the clinic and improve the lives of patients with diabetes.
Semma was founded by Douglas Melton, Ph.D. and others to develop transformative therapies for patients who currently depend on insulin injections. Semma recently announced the achievement of preclinical proof-of-concept for these two lead programs based on data in which they tested human stem cell-derived islets (SC-islets) in both non-human primates and pigs. This breakthrough technology has been exclusively licensed to Semma for the development of a cell-based therapy for diabetes. In addition to pursing direct intra-hepatic transplantation of these islet cells, ongoing research at Semma is focused on combining these proprietary cells with a state-of-the-art cell device and immune protection strategy that can protect these cells from the patient’s immune system and allow the beta cells to function as they do in non-diabetic individuals. Dr. Sanna will join Vertex as President of Semma.
Il caso Semma Therapeutics Un’altra società che dovrebbe portare il suo prodotto in clinica entro il 2020 (almeno secondo i piani pre-Covid) è Semma Therapeutics, biotech fondata da Doug Melton, co-direttore dell’Harvard stem cell institute (Hsci) di Boston, nel 2014 (il nome deriva da Sam ed Emma, suoi figli, entrambi affetti da diabete di tipo 1).
Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients.
The company is headquartered in Cambridge, MA, with operations in … Semma Therapeutics operates in the State of Massachusetts.200 Clarendon Street Website: http://www.semma-tx.com/ Semma Therapeutics is pioneering the new treatment paradigm of using cells as medicine.
The company is focused on advancing Dr. Melton’s method of generating billions of functional, insulin-producing beta cells grown from stem cells in the laboratory, which develop in islet-like clusters. Biotechnology to Create Transformative Medicines.
Boston, MA 02116 The company has three approved medicines that treat the underlying cause of cystic fibrosis (CF) - a rare, life-threatening genetic disease - and has several ongoing clinical and research programs in CF. Founded in 1989 in Cambridge, Mass., Vertex's global headquarters is now located in Boston's Innovation District and its international headquarters is in London, UK.
Those risks and uncertainties include, among other things, the transaction is subject to certain conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, Vertex may not realize the potential benefits of the acquisition, and the other risks listed under Risk Factors in Vertex's annual report and quarterly reports filed with the Securities and Exchange Commission and available through the company's website at Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) to acquire Semma Therapeutics to develop curative cell-based treatments for type 1 diabetes. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. These data were presented in a plenary session at the International Society for Stem Cell Research (ISSCR) in June 2019. The companies anticipate the acquisition will close in the fourth quarter of 2019, subject to certain conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions. About Semma Therapeutics. Recent work in the laboratory of Professor Douglas Melton led to the discovery of a method to generate billions of functional, insulin-producing beta cells in the laboratory. To date, Semma’s cell therapy approach is the only islet cell transplantation program to have demonstrated both positive c-peptide release (a marker of insulin secretion), as well as positive glycemic control of experimentally induced diabetes. Learn More.